Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Clinical Trials

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, July 18, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, June 28, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) today released a new report titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 New Jersey patients participate in clinical trials around the state, generating $617 million in economic growth.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas: Continue reading

Clinical Trials Awareness Week: Celebrating the Impact of Clinical Research

Washington, DC, May 4, 2017 — Andrew Powaleny reports on The Catalyst, PhRMA’s blog, that May 1 was the kick off of Clinical Trials Awareness Week, which shines a spotlight on how the clinical trials process helps deliver safe, effective medicines to patients.

Each year, hundreds of thousands of clinical trials are ongoing or underway and in the first four months of 2017 alone the number of clinical studies registered has already surpassed the total number registered in 2016, according to Clinicaltrials.gov.

These trials are essential to study the benefits and potential risks of new medicines. The U.S. Food and Drug Administration rely on this data to determine whether a new medicine is safe and effective. Continue reading

I-ACT for Children Launches to Promote Innovative Medicines Development for Young Patients in Need

Washington, DC, April 19, 2017 — Lucy Vereshchagina reports on PhRMA’s Catalyst blog that, in an exciting step forward to support research and development of innovative new medicines and devices for pediatric patients, the Critical Path Institute (C-Path) announced the launch of a new nonprofit to address challenges in bringing new therapies to children in need.

Called the Institute for Advanced Clinical Trials for Children (I-ACT for Children), this new organization will seek to foster public-private collaboration in finding solutions to barriers to pediatric medicines development as well as improving the pediatric clinical trials process.

Specifically, it will work to optimize pediatric study designs, protocols, best practices, training and engagement of patients and parents to advance clinical trials to improve children’s health. Continue reading

Drug Trial of an Antibody Therapy That Targets Alzheimer’s Disease Sparks Optimism

Alzheimer's WordsWashington, DC, September 2, 2016 — Tara Bahrampour reports in The Washington Post that an initial trial of an antibody therapy that targets Alzheimer’s disease has shown promising results and could signal a long-awaited breakthrough in treating the devastating brain disorder that affects over 5 million Americans.

The antibody, known as aducanumab, targets a protein called amyloid beta that builds up in the brain and creates plaques associated with the disease. In a paper published Wednesday in the journal Nature, a trial to evaluate the drug’s safety and tolerability showed positive results.

Of 165 patients, those who received monthly infusions of the drug for a year showed a significant reduction in amyloid beta and slower cognitive decline than those receiving a placebo. Continue reading

BioNJ Report: Clinical Trials Activity in New Jersey Delivers 3,750 Jobs and $779M in Economic Output

Clinical Trial 3

Trenton, NJ, June 24, 2016BioNJ, the trade association for New Jersey’s life sciences industry, yesterday released its “Economic Impact Study of Clinical Trials Activity in New Jersey” in collaboration with Rutgers Business School and Rutgers Bloustein School of Planning and Public Policy noting that clinical trials activity in New Jersey delivers 3,750 jobs and $779 million in economic output.

The first study of its kind in New Jersey, the research brief serves as a call for efforts to increase clinical trials capacity and resources in the State and for the education of all stakeholders as to the value delivered to the healthcare system through the conduct of clinical trials. Continue reading

Pharmalot: Study Show More Clinical Trials Are Succeeding for First Time in Years

Clinical Trial 3Boston, MA, June 14, 2016 ― Pharmalot reporter-blogger Ed Silverman reports on STAT News that after years of declines, the pharmaceutical industry is experiencing a greater rate of success with its clinical trials in recent years, according to a new analysis from McKinsey & Co.,

Between 2012 and 2014, more than 11 percent of clinical trials succeeded, which meant compounds being tested survived the arduous journey from the laboratory to the pharmacy counter.

This reversed a downward trend seen over the past 20 years, according to executives at McKinsey & Co., the consulting firm that conducted the analysis and does consulting work for drug makers. Continue reading

Biotechnology Innovation Organization Releases Largest Study Ever on Clinical Development Success Rates

BIO Logo New NameWashington, DC, May 30, 2016Biotechnology Innovation Organization (BIO) on May 25 released the largest ever study of clinical development success rates.  The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies.

Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success.

“This study provides a wealth of information about drug development success rates across a broad range of indications,” said Cartier Esham, PhD, BIO’s Executive Vice President, Emerging Companies. Continue reading

PhRMA Catalyst: May 2-6 Is Clinical Trials Awareness Week; PhRMA to Host Twitter Chat Thursday Noon #CTAW2016

Clinical Trials Awareness Week 206Washington, DC, May 2 ― Andrew Powaleny reports on The Catalyst, the Pharmaceutical Research and Manufacturers of America (PhRMA) blog, that clinical trials are the most effective way to find new, innovative treatments for illnesses patients may face.

However, misconceptions and lack of awareness about this important research often keep people from participating.  In fact, two thirds of trials fail to enroll enough participants.

This week, we celebrate Clinical Trials Awareness Week (May 2-6) to help people better understand clinical trials and feel empowered to get involved in the process.

A broad range of partners will focus on educating people on this critical process, particularly what is involved in clinical trials and how to find out if you or a loved one could potentially participate. Continue reading

Chairman Fred Upton: ‘21st Century Clinical Trials for 21st Century Cures’

Washington, DC, May 12, 2015 Congressman Fred Upton (R-MI-6), Chairman of the United States House of Representatives’ Committee on Energy and Commerce has written the following regarding the 21st Century Cures inititiave #Cures2015 that his committee has driven over the past year.

*    *    *

21st Century Cures is about embracing technological and scientific advancements to get treatments and cures to patients more quickly.  It’s a forward-looking approach to health care, using new strategies to fight disease rather than doing things the way they’ve been done in the past.

When a new drug or device is developed, it must go through a clinical trial to test its safety and effectiveness.  The gold standard for how these trials are conducted was developed decades ago, and a lot has changed since then.  Modernizing clinical trials is essential in achieving our health innovation goals. Continue reading